Get the Daily Brief
Latest Biotech News
Immutep’s LAG‑3 program halted — stock collapses, company scrambles
Immutep halted its Phase III TACTI‑004 trial of eftilagimod alfa (efti, IMP‑321) in first‑line non‑small‑cell lung cancer after an interim futility analysis, sending the company’s shares...
Ultragenyx gene therapy hits a primary endpoint in rare ammonia disorder trial
Ultragenyx reported that its gene therapy candidate for ornithine transcarbamylase (OTC) deficiency met one of two primary endpoints in a Phase 3 trial involving 37 patients with blood ammonia...
Vima ups Series A with $40m extension to push movement‑disorder candidates
Vima raised a $40 million extension to its Series A, taking total financing to $100 million to complete two Phase II trials in isolated dystonia and Parkinson’s disease. Investors in the tranche...
Engineered bacteria clear decades‑old bottleneck in doxorubicin manufacturing
An international consortium reported in Nature Communications that engineered a bacterial strain which resolves long‑standing molecular bottlenecks in the biosynthesis of the anthracycline...
Cytokine‑fusion scaffold produces long‑lived CAR‑T cells in preclinical models
Researchers at Albert Einstein College of Medicine described a manufacturing innovation that links IL‑7, IL‑15 and IL‑21 into a single protein scaffold (HCW9206) used during CAR‑T production. In...
Antibody‑siRNA conjugate reaches muscle—early DM1 trial shows target knockdown
The antibody‑siRNA conjugate delpacibart etedesiran (del‑desiran, AOC‑1001) demonstrated muscle delivery and DMPK mRNA depletion in Phase I/II MARINA trial data reported in NEJM. Investigators led...
China approves first commercial brain implant for spinal‑injury patients
Shanghai‑based Neuracle Medical Technology received Chinese regulatory approval to commercialize a coin‑sized wireless cortical brain‑computer interface (BCI) for patients with spinal cord...
Senolytic strategy clears therapy‑resistant cells in pancreatic cancer models
Researchers unveiled a senolytic therapeutic approach for pancreatic ductal adenocarcinoma (PDAC) that targets senescent tumor‑supporting cells and the KRAS–RB1 interaction, producing tumor...
Immutep’s phase III flop – Stock tumbles after futility stop
Immutep halted its phase III TACTI-004 trial of eftilagimod alfa (IMP-321, “efti”) in first-line non-small-cell lung cancer after an independent data monitoring committee recommended stopping for...
Lantheus wins tentative FDA ANDA – Patent battle with Novartis heats up
The FDA issued a tentative approval for Lantheus’ abbreviated new drug application (ANDA) for PNT2003, a generic version of Novartis’ radioligand Lutathera (lutetium Lu 177 dotatate), opening the...
HER2 ADC shows activity in urothelial cancer – High response rates in phase 2
Disitamab vedotin (DV), a HER2-targeted antibody–drug conjugate, produced robust response rates in a phase 2 RC48G001 study of previously treated locally advanced or metastatic urothelial...
Engineering CAR‑T persistence: cytokine scaffolds extend durability
Two independent approaches reported by researchers at Albert Einstein College of Medicine aim to solve CAR‑T cell persistence. One Science Advances paper described a modular protein scaffold...
Antibody‑siRNA conjugate reaches muscle—first signals in myotonic dystrophy trial
Delpacibart etedesiran (del‑desiran, AOC 1001), an antibody‑siRNA conjugate designed to silence DMPK in muscle, showed target engagement in the Phase I/II MARINA trial and achieved muscle DMPK...
Ultragenyx gene therapy clears a Phase 3 milestone in urea cycle disorder
Ultragenyx reported that its gene therapy candidate for ornithine transcarbamylase (OTC) deficiency met one of two co‑primary endpoints in a Phase 3 study involving 37 patients. The company...
Vitestro raises $70M to scale robotic blood draws – Push toward FDA De Novo
Vitestro closed a $70 million Series B to advance Aletta, an autonomous robotic phlebotomy device designed for high‑volume blood collection. The company plans clinical pilots, manufacturing...
Scientists unlock doxorubicin bottleneck – Engineered bacteria boost chemo production
An international consortium published work in Nature Communications identifying and engineering key biosynthetic steps that had limited microbial production of the anthracycline doxorubicin for...
Stanley Family adds $280M to Broad’s psychiatric genetics push
The Stanley Family Foundation committed an additional $280 million to the Broad Institute’s Stanley Center for Psychiatric Research, bringing the foundation’s total investment in the center to...
High‑throughput SPR moves upstream: Carterra’s Vega aims at primary screening
Carterra unveiled the Vega platform to scale surface plasmon resonance (SPR) to tens of thousands of interactions per day, positioning label‑free binding kinetics earlier in discovery workflows....
Immutep’s phase‑III flop – efti trial stopped for futility
Immutep announced that its Phase III TACTI‑004 trial of eftilagimod alfa (efti) in first‑line non‑small‑cell lung cancer was halted after an independent data monitoring committee recommended...
Lantheus wins tentative FDA ANDA nod amid Lutathera patent war
The FDA issued a tentative approval for Lantheus’ ANDA for PNT2003, a generic version of Novartis’ radioligand Lutathera (lutetium Lu 177 dotatate), used to treat somatostatin receptor‑positive...